Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Immune Balance Technologies (IBT) is a biotechnology company specializing in the discovery and development of natural products that modulate the immune system. Founded as a spin-off from the University of Mississippi's National Center for Natural Products Research, IBT utilizes a proprietary bioassay-guided fractionation platform to identify and standardize potent immune-enhancing compounds. The company's primary focus is on high-molecular-weight polysaccharides and botanical extracts that support immune health, particularly for individuals with compromised immune systems. Their lead technology is commercialized as the 'Immune Balance' dietary supplement, which is designed to optimize macrophage activity and enhance overall immune surveillance. IBT continues to conduct research into the molecular mechanisms of natural immunomodulators to support wellness and therapeutic applications.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Immune Balance Technologies.